<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068820</url>
  </required_header>
  <id_info>
    <org_study_id>SLN Mapping</org_study_id>
    <nct_id>NCT02068820</nct_id>
  </id_info>
  <brief_title>Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG</brief_title>
  <official_title>Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue (ISB) and Indocyanine Green Dyes (ICG) With Fluorescence Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AdventHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesis is that if sensitivity and specificity are found to be
      significantly higher than the current reports with Technesium-99 and ISB colorimetric dye,
      SLN biopsies might allow omission of full lymphadenectomy in lower-risk cases, thereby
      limiting peri-operative morbidity. SLN biopsies might also improve the detection of
      metastatic disease, essentially lowering the recognized false-negative rate of standard
      lymphadenectomy analyzed by routine H&amp;E pathologic analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to compare two sentinel lymph node detection technologies
      [fluorescence imaging and Indocyanine Green (ICG) dye verses standard laparoscopic
      colorimetric analysis using Isosulfan Blue (ISB) dye] for sensitivity and specificity of
      detecting metastatic disease in pelvic lymph nodes of women with endometrial cancer
      undergoing robotic-assisted laparoscopic hysterectomy and lymphadenectomy. The following
      three specific aims would be addressed in this research proposal:

      Specific Aim 1: To determine the ability of mapping bilaterally pelvic SLN in women with
      endometrial cancer undergoing robotic-assisted laparoscopic staging comparing two different
      methods (i.e., comparing the combination of colorimetric analysis-ISB dye + fluorescence
      imaging-ICG dye vs. colorimetric analysis-ISB dye alone).

      Specific Aim 2: To estimate the negative predictive value (NPV) of pelvic SLN in endometrial
      cancer with respect to predicting nodal metastasis.

      Specific Aim 3: To evaluate the ability of sentinel lymph nodes to increase the detection of
      metastatic disease through ultra-sectioning and immuno-histochemical (IHC) staining by
      comparing IHC results and standard hematoxylin and eosin (H&amp;E) results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes.</measure>
    <time_frame>through 6 weeks post-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative Predictive Value (NPV) of Pelvic SLN in Endometrial Cancer in Relation to the Number of Nodes With Metastasis.</measure>
    <time_frame>through 6 weeks post-operative</time_frame>
    <description>The standard definition for negative predictive value was used to calculate NPV. There was one false negative SLN in this study, 39 true positive sentinel lymph nodes, and 140 negative pelvic metastatic patients.
NPV = 140/141=99.3%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Pelvic Sentinal Lymph Nodal Metastasis in Regard to Staining by Immunohistochemical (IHC) Staining in Comparison to Standard Hematoxylin and Eosin (H&amp;E).</measure>
    <time_frame>through 6 weeks post-operative</time_frame>
    <description>Of the 127 positive nodes with pathology information, the percentage of each type of node will be summarized by the staining method. Statistical testing of the individual staining methods compared to both will be computed using Chi-square test of independence.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>ISB dye, standard white light</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICG dye, FireFly fluorescence imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ISB dye and standard white light imaging</intervention_name>
    <description>Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.</description>
    <arm_group_label>ICG dye, FireFly fluorescence imaging</arm_group_label>
    <arm_group_label>ISB dye, standard white light</arm_group_label>
    <other_name>Isosulfan Blue dye</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICG dye and FireFly fluorescence imaging</intervention_name>
    <description>Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.</description>
    <arm_group_label>ICG dye, FireFly fluorescence imaging</arm_group_label>
    <other_name>Indocyanine green dye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be ≥18 and ≤85 years of age.

          2. The patient must be female.

          3. The patient must be willing and able to provide informed consent.

          4. The patient is willing and able to comply with the study protocol.

          5. The patient has endometrial cancer and is scheduled for robotic hysterectomy and
             lymphadenectomy.

          6. The patient agrees to follow-up examinations out to 6-weeks post-treatment

        Exclusion Criteria:

          1. The patient is not a candidate for robotic assisted hysterectomy and lymphadenectomy.

          2. The patient has known or suspected allergies to iodine, ICG or ISB.

          3. The patient has hepatic dysfunction confirmed by elevated liver function studies
             (i.e., hepatic enzyme SGOT, SGPT or Bilirubin &gt; 2 x normal (based on reference values
             from the laboratory used by the patient)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Holloway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Gynecologic Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital Gynecologic Oncology</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <results_first_submitted>December 18, 2017</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sentinel lymph nodes</keyword>
  <keyword>da Vinci</keyword>
  <keyword>Firefly</keyword>
  <keyword>Sentinel lymph node mapping</keyword>
  <keyword>Fluorescence Imaging</keyword>
  <keyword>SLN</keyword>
  <keyword>SLN mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorophosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ISB Dye, Standard White Light</title>
          <description>SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.</description>
        </group>
        <group group_id="P2">
          <title>ICG Dye, FireFly Fluorescence Imaging</title>
          <description>SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
ICG dye and FireFly fluorescence imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ISB Dye, Standard White Light</title>
          <description>SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.</description>
        </group>
        <group group_id="B2">
          <title>ICG Dye, FireFly Fluorescence Imaging</title>
          <description>SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
ICG dye and FireFly fluorescence imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="6.7"/>
                    <measurement group_id="B2" value="64.4" spread="8.6"/>
                    <measurement group_id="B3" value="64.5" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes.</title>
        <time_frame>through 6 weeks post-operative</time_frame>
        <population>The ISB dye alone group (n=20) and the ICG group (n=180) are combined, because both groups received the ISB dye.</population>
        <group_list>
          <group group_id="O1">
            <title>ISB Dye, Standard White Light</title>
            <description>SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.</description>
          </group>
          <group group_id="O2">
            <title>ICG Dye, FireFly Fluorescence Imaging</title>
            <description>SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
ISB dye and standard white light imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
ICG dye and FireFly fluorescence imaging: Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes.</title>
          <population>The ISB dye alone group (n=20) and the ICG group (n=180) are combined, because both groups received the ISB dye.</population>
          <units>nodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread=".901"/>
                    <measurement group_id="O2" value="2.03" spread=".720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Negative Predictive Value (NPV) of Pelvic SLN in Endometrial Cancer in Relation to the Number of Nodes With Metastasis.</title>
        <description>The standard definition for negative predictive value was used to calculate NPV. There was one false negative SLN in this study, 39 true positive sentinel lymph nodes, and 140 negative pelvic metastatic patients.
NPV = 140/141=99.3%</description>
        <time_frame>through 6 weeks post-operative</time_frame>
        <population>Comparison of metastatic disease (yes or no) with ICG dye node detection (yes or no)</population>
        <group_list>
          <group group_id="O1">
            <title>ICG Negative</title>
            <description>Experimental subjects with Indocyanine Green (ICG) negative test results</description>
          </group>
          <group group_id="O2">
            <title>ICG Positive</title>
            <description>Experimental subjects with Indocyanine Green (ICG) positive test results</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value (NPV) of Pelvic SLN in Endometrial Cancer in Relation to the Number of Nodes With Metastasis.</title>
          <description>The standard definition for negative predictive value was used to calculate NPV. There was one false negative SLN in this study, 39 true positive sentinel lymph nodes, and 140 negative pelvic metastatic patients.
NPV = 140/141=99.3%</description>
          <population>Comparison of metastatic disease (yes or no) with ICG dye node detection (yes or no)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Metastatic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non Metastatic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Pelvic Sentinal Lymph Nodal Metastasis in Regard to Staining by Immunohistochemical (IHC) Staining in Comparison to Standard Hematoxylin and Eosin (H&amp;E).</title>
        <description>Of the 127 positive nodes with pathology information, the percentage of each type of node will be summarized by the staining method. Statistical testing of the individual staining methods compared to both will be computed using Chi-square test of independence.</description>
        <time_frame>through 6 weeks post-operative</time_frame>
        <population>These are positive sentinel lymph nodes</population>
        <group_list>
          <group group_id="O1">
            <title>IHC Only</title>
            <description>Positive node identified with IHC dye only</description>
          </group>
          <group group_id="O2">
            <title>H&amp;E Only</title>
            <description>Positive node identified with H&amp;E only</description>
          </group>
          <group group_id="O3">
            <title>Both IHC and H&amp;E</title>
            <description>Positive node identified with both IHC and H&amp;E dye</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pelvic Sentinal Lymph Nodal Metastasis in Regard to Staining by Immunohistochemical (IHC) Staining in Comparison to Standard Hematoxylin and Eosin (H&amp;E).</title>
          <description>Of the 127 positive nodes with pathology information, the percentage of each type of node will be summarized by the staining method. Statistical testing of the individual staining methods compared to both will be computed using Chi-square test of independence.</description>
          <population>These are positive sentinel lymph nodes</population>
          <units>nodes</units>
          <param>Number</param>
          <units_analyzed>Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="NA"/>
                <count group_id="O2" value="NA"/>
                <count group_id="O3" value="NA"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sentinel Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic Nodes Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aortic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infrarenal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Post-op follow up 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISB Only Adverse Events</title>
          <description>ISB only Adverse Events categories reported during post-op follow up 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>ICG Adverse Events</title>
          <description>ICG Adverse Events categories reported during post-op follow up 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system complications</sub_title>
                <description>The following were effected:
Leukocytosis Anemia Thrombocytopenia Neutropenia Lymphatic ascites</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac complications</sub_title>
                <description>The following were effected:
Cardiac complications Tachycardia Atrial fibrillation</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal complications</sub_title>
                <description>The following were effected:
Small bowel obstruction</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <description>The following were effected:
Hypotension Hypertension Lymphedema Fever</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary complications</sub_title>
                <description>The following were effected:
Acute renal insufficiency Polyuria Transient right hydronephrosis Urinary retention</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system complications</sub_title>
                <description>The following were effected:
Vaginal discharge Vasomotor symptoms Vaginal spotting Uterovaginal fistula Vaginal bleeding Pelvic abscess Vaginal leakage</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic, and pulmonary complications</sub_title>
                <description>The following were effected:
Pulmonary embolism Pleural effusions Pneumothorax</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>The following were effected:
Cellulitis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound complications</sub_title>
                <description>The following were effected:
Wound dehiscence Wound seroma Left incisional drainage</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular complications</sub_title>
                <description>The following were effected:
Deep Vein Thrombosis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert W. Holloway</name_or_title>
      <organization>Florida Hospital Gynecologic Oncology</organization>
      <phone>407-303-2400</phone>
      <email>robhollowaymd@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

